miRNA

GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.

The company, which is also developing a therapeutic for the liver disease, plans to pursue regulatory approval in the US and Europe.

The collaborators are developing tests for rectal cancer based on microRNA and messenger RNA signatures.